Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 991 of 6351
-
New drug combo offers hope for hard-to-treat thyroid cancer
Disease control OngoingThis phase II trial studies how well encorafenib and binimetinib given with or without nivolumab works in treating patients with BRAF V600 mutation positive thyroid cancer that has spread to other places in the body (metastatic) and does not respond to radioiodine treatment (refr…
Phase 2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Brain cancer hope: new drug cocktail targets rare lymphoma
Disease control OngoingThis study is to improve the first-line induction chemotherapy, by combining either Ibrutinib, or Lenalidomide, to a conventional immuno- chemotherapy of R-MPV type (Rituximab-Methotrexate-Procarbazine-Vincristine). This is a randomized Phase II trial, preceded by a dose escalati…
Phase 1/2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Can a protein calm the immune System's overreaction to cancer treatment?
Disease control Stopped earlyThis phase I/II trial investigates the side effects and how well CD24Fc works in treating immune related adverse events in patients with solid tumors that have spread to other places in the body (advanced). CD24Fc may prevent autoimmune reactions due to the tissue damage induced …
Phase 1/2 • Sponsor: Tianhong Li • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New cocktail of drugs shows promise for Tough-to-Treat melanoma
Disease control OngoingThe primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Could a common painkiller help preterm Babies' hearts?
Disease control CompletedTREOCAPA is a Phase II/III European Multicentre study concerning the prophylactic treatment by Acetaminophen of extremely preterm infant during the first five days after birth. The Phase II is a dose finding phase in order to assess the minimum effective dose regimen of acetamin…
Phase 2/3 • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New pill targets rare cancer mutation in early trial
Disease control Recruiting nowThe Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will asses…
Phase 1/2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug combo shows promise for Tough-to-Treat hairy cell leukemia
Disease control OngoingBackground: Hairy cell leukemia (HCL) does not usually respond to chemotherapy. Most people with HCL have a BRAF gene mutation. This can increase the growth of cancer cells. Vemurafenib has been tested to treat these people. However, researchers think a combination of drugs migh…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo therapy shows promise for untreatable liver cancer
Disease control OngoingThis is a retrospective, multicenter, real-world cohort study designed to evaluate the effectiveness and safety of atezolizumab plus bevacizumab (Atezo+Bev) combined with various locoregional therapies (LRTs), including transarterial chemoembolization (TACE), hepatic arterial inf…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Could an asthma drug tame this brutal blistering disease?
Disease control CompletedThe main purpose of this study is to investigate whether dupilumab is effective and safe for the treatment of bullous pemphigoid. Dupilumab is a type of drug called a "monoclonal antibody". An antibody is a special kind of protein that the immune (defense) system normally makes t…
Phase 2/3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Brain bleed breakthrough? new study tests artery blocking to avoid surgery
Disease control CompletedThe purpose of this study is to evaluate the safety and efficacy of embolization of the middle meningeal artery (MMA) using the Onyx™ Liquid Embolic System (LES) for treatment of symptomatic subacute or chronic subdural hematoma (SDH)
Sponsor: Medtronic Neurovascular Clinical Affairs • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Gene therapy trial hopes to treat rare muscle disease
Disease control OngoingThis is a phase 1/2 open-label, ascending dose, multicenter clinical study to evaluate the safety and efficacy of AT845 in adult (aged ≥ 18 years) subjects, ambulatory or nonambulatory, with Late Onset Pompe Disease (LOPD).
Phase 1/2 • Sponsor: Astellas Gene Therapies • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for rare blood cancer: experimental drug IMC-001 tested in 23 patients
Disease control OngoingThis is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type
Phase 2 • Sponsor: ImmuneOncia Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New daily pill could rival infusion for slowing progressive MS
Disease control OngoingA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocr…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New 'Chemical Sniffer' could help surgeons find brain tumors Mid-Operation
Diagnosis PausedThis study explores whether DESI-MS can be used to identify cancerous vs. noncancerous tissue during brain tumor surgery.
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 08:07 UTC
-
New combo aims to keep lung cancer at bay after chemo
Disease control CompletedThis is a multicenter, randomized, double-blind, placebo-controlled study of niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance therapy in participants with advanced or metastatic non-small cell lung cancer (NSCLC) who have achieved stable disease (SD),…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy drug aims to stop rare skin cancer's return
Disease control OngoingThe I-MAT trial is a randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma aiming to explore the efficacy of avelumab as adjuvant immunotherapy.
Phase 2 • Sponsor: Melanoma and Skin Cancer Trials Limited • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
CT scan could spare many heart attack patients from invasive procedures
Diagnosis OngoingNon ST-elevation myocardial infarction (NSTEMI) represents 70-75% of all myocardial infarctions. Current guidelines recommend invasive angiography and this patient group represents a major burden on the invasive catheterization laboratories and the health care system. The corona…
Sponsor: St. Olavs Hospital • Aim: Diagnosis
Last updated Aug 13, 2026 00:00 UTC
-
Immunotherapy plus chemo shows promise for tough sarcomas
Disease control Recruiting nowThe aim of this study was to investigate the efficacy and safety of CAV/IE chemotherapy combined with toripalimab versus CAV/IE chemotherapy alone in the treatment of patients with advanced or unresectable bone and soft tissue sarcomas who failed in standard treatment.
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Promising drug targets Hard-to-Treat breast cancer in chinese patients
Disease control OngoingThe goal of this study is to learn more about the effectiveness of the study drug, sacituzumab govitecan-hziy, in Chinese participants with metastatic triple-negative breast cancer (mTNBC) who received at least 2 systemic chemotherapy regimens.
Phase 2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New combo aims to cut rectal cancer treatment time and boost cure rates
Disease control OngoingThe treatment protocol proposed in this study is to perform short-term radiation therapy and 4 cycles of FOLFOX chemotherapy for neoadjuvant treatment of locally advanced rectal cancer. Compared to conventional chemoradiation therapy, the preoperative radiotherapy period is short…
Phase 2 • Sponsor: Kyungpook National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC